A postreconstruction harmonization method for multicenter radiomic studies in PET F Orlhac, S Boughdad, C Philippe, H Stalla-Bourdillon, C Nioche, ... Journal of Nuclear Medicine 59 (8), 1321-1328, 2018 | 336 | 2018 |
Breast cancer recurrence diagnosis suspected on tumor marker rising: Value of whole‐body 18FDG‐PET/CT imaging and impact on patient management L Champion, E Brain, AL Giraudet, E Le Stanc, M Wartski, V Edeline, ... Cancer 117 (8), 1621-1629, 2011 | 112 | 2011 |
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study N Mortazavi-Jehanno, AL Giraudet, L Champion, F Lerebours, E Le Stanc, ... European journal of nuclear medicine and molecular imaging 39, 450-460, 2012 | 65 | 2012 |
Single photon emission tomography/computed tomography (SPET/CT) and positron emission tomography/computed tomography (PET/CT) to image cancer JL Alberini, V Edeline, AL Giraudet, L Champion, B Paulmier, O Madar, ... Journal of surgical oncology 103 (6), 602-606, 2011 | 43 | 2011 |
Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab RD Seban, JB Assié, E Giroux-Leprieur, MA Massiani, M Soussan, ... Cancers 12 (8), 2234, 2020 | 36 | 2020 |
18F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer L Champion, F Lerebours, P Cherel, V Edeline, AL Giraudet, M Wartski, ... European journal of nuclear medicine and molecular imaging 40, 1206-1213, 2013 | 35 | 2013 |
18F-FDG PET/CT to predict response to neoadjuvant chemotherapy and prognosis in inflammatory breast cancer L Champion, F Lerebours, JL Alberini, E Fourme, E Gontier, F Bertrand, ... Journal of Nuclear Medicine 56 (9), 1315-1321, 2015 | 32 | 2015 |
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo-or immunotherapy RD Seban, JB Assié, E Giroux-Leprieur, MA Massiani, G Bonardel, ... Lung Cancer 159, 45-55, 2021 | 30 | 2021 |
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer RD Seban, JB Assie, E Giroux-Leprieur, MA Massiani, M Soussan, ... Annals of Nuclear Medicine 34, 968-974, 2020 | 29 | 2020 |
Primary lymphedema French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins) S Vignes, J Albuisson, L Champion, J Constans, V Tauveron, J Malloizel, ... Orphanet Journal of Rare Diseases 16, 1-12, 2021 | 25 | 2021 |
Primary and secondary breast angiosarcoma: FDG PET/CT series T Cassou-Mounat, L Champion, L Bozec, V Laurence, V Huchet, ... Clinical nuclear medicine 44 (1), e33-e35, 2019 | 19 | 2019 |
Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer RD Seban, R Rouzier, A Latouche, N Deleval, JM Guinebretiere, I Buvat, ... European Journal of Nuclear Medicine and Molecular Imaging 48, 3560-3570, 2021 | 18 | 2021 |
Spleen glucose metabolism on [18F]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients RD Seban, L Champion, LH Schwartz, L Dercle European Journal of Nuclear Medicine and Molecular Imaging 48, 2309-2311, 2021 | 14 | 2021 |
Immune response visualized in vivo by [18F]-FDG PET/CT after COVID-19 vaccine RD Seban, L Champion, N Deleval, C Richard, C Provost Diagnostics 11 (4), 676, 2021 | 14 | 2021 |
Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response S Boughdad, L Champion, V Becette, P Cherel, E Fourme, J Lemonnier, ... Cancer Imaging 20, 1-9, 2020 | 14 | 2020 |
Influence of age on radiomic features in 18F-FDG PET in normal breast tissue and in breast cancer tumors S Boughdad, C Nioche, F Orlhac, L Jehl, L Champion, I Buvat Oncotarget 9 (56), 30855, 2018 | 13 | 2018 |
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial M Rodrigues, G Vanoni, P Loap, C Dubot, E Timperi, M Minsat, L Bazire, ... Nature Communications 14 (1), 3698, 2023 | 12 | 2023 |
Voxel‐wise supervised analysis of tumors with multimodal engineered features to highlight interpretable biological patterns T Escobar, S Vauclin, F Orlhac, C Nioche, P Pineau, L Champion, ... Medical Physics 49 (6), 3816-3829, 2022 | 12 | 2022 |
Absolute lymphocyte count after COVID-19 vaccination is Associated with Vaccine-Induced Hypermetabolic Lymph Nodes on 18F-FDG PET/CT: a focus in breast Cancer Care RD Seban, C Richard, C Nascimento-Leite, J Ghidaglia, C Provost, ... Journal of Nuclear Medicine 63 (8), 1231-1238, 2022 | 11 | 2022 |
Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas O Bélissant, L Champion, H Thevenet, P Weinmann, JL Alberini Nuclear medicine communications 39 (7), 652-658, 2018 | 8 | 2018 |